Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Neeta Pandit-Taskar

Showing results (161-170 of 181) with videos related to

Pageof 19
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 5, 2019
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using <sup>89</sup>Zr-DFO-MSTP2109A Anti-STEAP1 AntibodyJorge A Carrasquillo, Bernard M Fine, Neeta Pandit-Taskar, et al.
Molecular Pharmaceutics|May 24, 2019
Pharmacokinetics and Biodistribution of a [<sup>89</sup>Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer PatientsJoseph A O'Donoghue, Daniel C Danila, Neeta Pandit-Taskar, et al.
The Lancet. Oncology|September 13, 2024
[<sup>89</sup>Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trialBrian Shuch, Allan J Pantuck, Jean-Christophe Bernhard, et al.
Journal of Hematology & Oncology|November 12, 2022
Phase 1 study of intraventricular <sup>131</sup>I-omburtamab targeting B7H3 (CD276)-expressing CNS malignanciesKim Kramer, Neeta Pandit-Taskar, Brian H Kushner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 19, 2011
(124)I-huA33 antibody PET of colorectal cancerJorge A Carrasquillo, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2019
First-in-Humans Imaging with <sup>89</sup>Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion TargetingNeeta Pandit-Taskar, Michael A Postow, Matthew D Hellmann, et al.
Molecular Cancer Therapeutics|October 20, 2021
Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal CarcinomatosisChristopher S Chandler, Meghan M Bell, Sebastian K Chung, et al.
Pediatric Blood & Cancer|September 24, 2017
A phase II study of radioimmunotherapy with intraventricular <sup>131</sup> I-3F8 for medulloblastomaKim Kramer, Neeta Pandit-Taskar, John L Humm, et al.
British Journal of Haematology|January 14, 2026
Prognostic role of PET/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL GroupS Claire Gowdy, Jamie E Flerlage, Jennifer Seelisch, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 22, 2014
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancerNeeta Pandit-Taskar, Joseph A O'Donoghue, Volkan Beylergil, et al.
Pageof 19

Showing results (161-170 of 181) with videos related to

Sort By:
Pageof 19
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|May 5, 2019
Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using <sup>89</sup>Zr-DFO-MSTP2109A Anti-STEAP1 AntibodyJorge A Carrasquillo, Bernard M Fine, Neeta Pandit-Taskar, et al.
Molecular Pharmaceutics|May 24, 2019
Pharmacokinetics and Biodistribution of a [<sup>89</sup>Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer PatientsJoseph A O'Donoghue, Daniel C Danila, Neeta Pandit-Taskar, et al.
The Lancet. Oncology|September 13, 2024
[<sup>89</sup>Zr]Zr-girentuximab for PET-CT imaging of clear-cell renal cell carcinoma: a prospective, open-label, multicentre, phase 3 trialBrian Shuch, Allan J Pantuck, Jean-Christophe Bernhard, et al.
Journal of Hematology & Oncology|November 12, 2022
Phase 1 study of intraventricular <sup>131</sup>I-omburtamab targeting B7H3 (CD276)-expressing CNS malignanciesKim Kramer, Neeta Pandit-Taskar, Brian H Kushner, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|July 19, 2011
(124)I-huA33 antibody PET of colorectal cancerJorge A Carrasquillo, Neeta Pandit-Taskar, Joseph A O'Donoghue, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|October 6, 2019
First-in-Humans Imaging with <sup>89</sup>Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion TargetingNeeta Pandit-Taskar, Michael A Postow, Matthew D Hellmann, et al.
Molecular Cancer Therapeutics|October 20, 2021
Intraperitoneal Pretargeted Radioimmunotherapy for Colorectal Peritoneal CarcinomatosisChristopher S Chandler, Meghan M Bell, Sebastian K Chung, et al.
Pediatric Blood & Cancer|September 24, 2017
A phase II study of radioimmunotherapy with intraventricular <sup>131</sup> I-3F8 for medulloblastomaKim Kramer, Neeta Pandit-Taskar, John L Humm, et al.
British Journal of Haematology|January 14, 2026
Prognostic role of PET/CT volumetric parameters in paediatric Hodgkin lymphoma: A systematic review and expert recommendations from the International SEARCH for CAYAHL GroupS Claire Gowdy, Jamie E Flerlage, Jennifer Seelisch, et al.
European Journal of Nuclear Medicine and Molecular Imaging|August 22, 2014
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancerNeeta Pandit-Taskar, Joseph A O'Donoghue, Volkan Beylergil, et al.
Pageof 19